Elevation Oncology, Inc. (ELEV) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, NY, United States. The current CEO is Joseph J. Ferra Jr..
ELEV has IPO date of 2021-06-25, 34 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $21.63M.
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
